DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 Voorraadrapport

Marktkapitalisatie: CN¥18.2b

DaShenLin Pharmaceutical Group Toekomstige groei

Future criteriumcontroles 4/6

DaShenLin Pharmaceutical Group zal naar verwachting groeien in winst en omzet met respectievelijk 29.9% en 16.6% per jaar. De winst per aandeel zal naar verwachting groeien met 30.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 17.6% zijn.

Belangrijke informatie

29.9%

Groei van de winst

30.7%

Groei van de winst per aandeel

Consumer Retailing winstgroei42.7%
Inkomstengroei16.6%
Toekomstig rendement op eigen vermogen17.6%
Dekking van analisten

Good

Laatst bijgewerkt01 Nov 2024

Recente toekomstige groei-updates

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Winst- en omzetgroeiprognoses

SHSE:603233 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202638,6211,7162,3423,72612
12/31/202532,7991,4492,0533,32512
12/31/202426,9011,0552,7173,3916
9/30/202426,5398501,4883,202N/A
6/30/202425,8859071,6343,464N/A
3/31/202425,3361,0682,0493,648N/A
12/31/202324,5311,1661,3773,174N/A
9/30/202324,1541,2872,0554,160N/A
6/30/202323,5191,2391,8463,815N/A
3/31/202322,5181,1482,5293,843N/A
12/31/202221,2481,0362,7223,757N/A
9/30/202219,2228961,2602,411N/A
6/30/202218,4258601,0272,237N/A
3/31/202217,3778353841,708N/A
12/31/202116,7597912601,555N/A
9/30/202116,4461,0136821,833N/A
6/30/202115,6971,1131,0972,066N/A
3/31/202115,2801,1221,2862,145N/A
12/31/202014,5831,0621,1621,954N/A
9/30/202013,5931,0141,4301,966N/A
6/30/202012,8299171,2291,759N/A
3/31/202011,9257991,2251,779N/A
12/31/201911,1417031,2061,708N/A
9/30/201910,6016741,1721,462N/A
6/30/201910,0296248521,285N/A
3/31/20199,4045696131,119N/A
12/31/20188,859532319874N/A
9/30/20188,421522-118663N/A
6/30/20188,003515N/A553N/A
3/31/20187,718505N/A511N/A
12/31/20177,421475N/A648N/A
9/30/20176,992462N/A545N/A
6/30/20176,824458N/A497N/A
3/31/20176,545433N/A502N/A
12/31/20166,274430N/A496N/A
6/30/20165,681427N/A406N/A
3/31/20165,464415N/A445N/A
12/31/20155,265395N/A469N/A
12/31/20144,545266N/A449N/A
12/31/20133,707197N/A288N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 603233 ( 29.9% per jaar) ligt boven de spaarquote ( 2.9% ).

Winst versus markt: De winst van 603233 ( 29.9% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 25.8% per jaar).

Hoge groeiwinsten: De winst van 603233 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 603233 ( 16.6% per jaar) zal naar verwachting sneller groeien dan de markt CN ( 14.1% per jaar).

Hoge groei-inkomsten: De omzet van 603233 ( 16.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 603233 zal naar verwachting over 3 jaar laag zijn ( 17.6 %).


Ontdek groeibedrijven